Modality
Small Molecule
MOA
CD3xCD20
Target
TIM-3
Pathway
Epigenetic
PTSD
Development Pipeline
Preclinical
~Sep 2017
→ ~Dec 2018
Phase 1
~Mar 2019
→ ~Jun 2020
Phase 2
Sep 2020
→ Jun 2028
Phase 2Current
NCT08108054
1,170 pts·PTSD
2020-09→2028-06·Recruiting
1,170 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-06-082.2y awayPh2 Data· PTSD
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P2
Recruit…
Catalysts
Ph2 Data
2028-06-08 · 2.2y away
PTSD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08108054 | Phase 2 | PTSD | Recruiting | 1170 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Doxazasiran | Axsome | Phase 1 | TIM-3 |